[ad_1]
Samsung Biologics (CEO Kim Tae-han) held the groundbreaking ceremony of the world’s largest plant 4 at the Incheon Songdo global campus on the 18th. Considering the COVID-19 situation, this event was held as a blasting ceremony. Simplified virtual without aggregation.
The company plans to meet the target schedule by focusing on actual construction work. Construction of the fourth plant is expected to be partially completed in 2022 and fully operational in 2023.
The fourth plant has a production of 256,000 liters, beating the record for the third plant (180,000 liters), the world’s largest production facility based on a single plant. The total area of the plant is approximately 238,000 m2 (72,000 pyeong), and the total area of the plant of the first, second and third factories is 240,000 m2 (73,000 pyeong).
In particular, the fourth plant was designed as a “super plant” that provides a “one-stop service” within a plant, from cell line development to finished product production. Through this, the global biopharmaceutical supply rate is expected to increase dramatically and customer satisfaction to be maximized, ushering in an era of super differential competitiveness.
A Samsung Biologics official said, “A total of 1.74 trillion won is invested in the construction of the factory alone, and if the second site of the biocampus is secured, the total investment cost will be more than 2 trillion won. “. Approximately 6400 people are employed. The production induction effect is approximately 5.7 trillion won and the job creation effect is about 27,000 people. ”
Samsung Biologics locates the centerpieces going to the fourth floor, contributing to the government’s policy of fostering the materials, parts and equipment industries.
On this day, Samsung Biologics signed a memorandum of understanding with Jeonghyun Plant, a national incubator manufacturing company, and decided to supply all the various types of incubators entering the fourth factory from the Jeonghyun plant.
Although the incubator is a key facility that proliferates live cells on a large scale, it was difficult to locate due to the limitation of domestic technology, but Samsung Biologics is the Jeonghyun plant to reduce costs and improve productivity by locating technologies and facilities that depended of imports. Initiate localization in association with
Previously, in 2016, Samsung Biologics signed a contract to supply cleaners and disinfectants for cleaning the interior of production facilities with a national company, Viox, and paved the way for localization of the biological raw materials industry.
Viox, which successfully entered the market of biological raw materials and subsidiaries with the comprehensive support of Samsung Biologics, expanded its product supplier to other domestic companies and then exported technology to Singapore and advanced in the global market.
Samsung Biologics plans to continually promote localization projects as domestic companies are expected to expand overseas expansion by cooperating with our company and ultimately lead to the vitalization of the domestic economy.
Taehan Kim, President of Samsung Biologics, said: “We will continue to invest and develop biopharmaceuticals and technological innovation, promote the global status of K-Bio through market development, revitalize the economy by expanding exports and creating jobs for young people. . I will take the initiative to improve the quality of life. “
Meanwhile, Samsung Biologics plans to open the ‘Fourth Factory Online Promotion Center’ in the next month. The online PR room plans to provide real-time information, including the innovative design, features, and construction process of the fourth factory.
Copyright © GreenPost Korea Unauthorized reproduction and redistribution prohibited
[ad_2]
